Imagine Trial
Initiating therapy with the ACE inhibitor quinapril within the first 7 days after coronary artery bypass graft (CABG) surgery does not lead to better outcomes among patients already receiving optimal therapy, said Wiek H. van Gilst, MD, lead investigator of IMAGINE (Ischemia Management with Accupril Post Bypass Graft via Inhibition of Angiotensin Converting Enzyme).
Initiating therapy with the ACE inhibitor quinapril within the first 7 days after coronary artery bypass graft (CABG) surgery does not lead to better outcomes among patients already receiving optimal therapy, said Wiek H. van Gilst, MD, lead investigator of IMAGINE (Ischemia Management with Accupril Post Bypass Graft via Inhibition of Angiotensin Converting Enzyme). The results from IMAGINE were presented at the European Society of Cardiology Congress 2005 in Stockholm, Sweden.
"The results suggest that current optimal treatment is not improved by the addition of an ACE inhibitor for patients who do not have a previous clinical need for the drug," said Dr van Gilst, professor of cardiovascular and clinical pharmacology, University Medical Center Groningen, The Netherlands. Background therapy included a high rate of statins, beta blockers, and aspirin, he noted.
In IMAGINE, 2,553 patients who had undergone CABG in the previous 7 days were randomized to quinapril 40 mg/d or placebo. The premise was that the endothelial dysfunction and inflammation that is common after CABG would be treated effectively with ACE inhibition. Other than the need for CABG, the population was relatively low-risk, with only 39% having a history of MI and only 10% having diabetes.
The results "warrant caution when starting an ACE inhibitor in the early phase post-CABG in a low-risk population treated with contemporary therapy," said Dr van Gilst.
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More
